Beijing SL Pharmaceutical Co., Ltd.
Symbol: 002038.SZ
SHZ
8.62
CNYDzisiejsza cena rynkowa
31.0841
Wskaźnik P/E
2.4867
Wskaźnik PEG
8.86B
Kapitalizacja MRK
- 0.01%
Rentowność DIV
Beijing SL Pharmaceutical Co., Ltd. (002038-SZ) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5056.78 | 2133 | 739.9 | 990.2 | |||||||||||||||||||||||
balance-sheet.row.short-term-investments | 2289.51 | 1449.2 | 144.9 | 162.4 | |||||||||||||||||||||||
balance-sheet.row.net-receivables | 1134.59 | 236.2 | 406.4 | 534 | |||||||||||||||||||||||
balance-sheet.row.inventory | 625.05 | 144.5 | 136.8 | 124.8 | |||||||||||||||||||||||
balance-sheet.row.other-current-assets | 2585.99 | 126.3 | 714.5 | 648.7 | |||||||||||||||||||||||
balance-sheet.row.total-current-assets | 9402.41 | 2640 | 1997.7 | 2297.7 | |||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 2044.8 | 538.4 | 527.3 | 604 | |||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.intangible-assets | 4425.3 | 1143.7 | 978.5 | 872.8 | |||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 4425.3 | 1143.7 | 978.5 | 872.8 | |||||||||||||||||||||||
balance-sheet.row.long-term-investments | 5601.25 | 1587.3 | 1295.1 | 1241.3 | |||||||||||||||||||||||
balance-sheet.row.tax-assets | 77.69 | 0 | 39.5 | 27.7 | |||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3192.71 | 368.4 | 1037.7 | 717 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 15341.75 | 3637.8 | 3878.2 | 3462.7 | |||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.total-assets | 24744.16 | 6277.8 | 5875.8 | 5760.5 | |||||||||||||||||||||||
balance-sheet.row.account-payables | 778.6 | 213.2 | 176.2 | 191.4 | |||||||||||||||||||||||
balance-sheet.row.short-term-debt | 46.32 | 37.6 | -27.9 | 0.2 | |||||||||||||||||||||||
balance-sheet.row.tax-payables | 11.48 | 0 | 9 | 16.3 | |||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 2.2 | |||||||||||||||||||||||
Deferred Revenue Non Current | 185.63 | 47 | 51.4 | 56.2 | |||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 223.42 | - | - | - | |||||||||||||||||||||||
balance-sheet.row.other-current-liab | 379.81 | 107.3 | 112.7 | 1.6 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 362.01 | 47.4 | 107.8 | 109.3 | |||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 2.2 | |||||||||||||||||||||||
balance-sheet.row.total-liab | 1621.95 | 420.7 | 396.6 | 434.2 | |||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.common-stock | 4109.4 | 1027.3 | 1027.3 | 1027.3 | |||||||||||||||||||||||
balance-sheet.row.retained-earnings | 16182.54 | 4077.8 | 3763.8 | 3632.1 | |||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2743.99 | 695.1 | 676.5 | 651.9 | |||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0.86 | 0.4 | 0.4 | 0.1 | |||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 23036.79 | 5800.6 | 5468.1 | 5311.5 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 24744.16 | 6277.8 | 5875.8 | 5760.5 | |||||||||||||||||||||||
balance-sheet.row.minority-interest | 38.37 | 9.4 | 11.2 | 14.7 | |||||||||||||||||||||||
balance-sheet.row.total-equity | 23075.16 | 5810 | 5479.2 | 5326.2 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 24744.16 | - | - | - | |||||||||||||||||||||||
Total Investments | 7890.75 | 3036.4 | 1440.1 | 1403.6 | |||||||||||||||||||||||
balance-sheet.row.total-debt | 75.19 | 37.6 | 0 | 2.5 | |||||||||||||||||||||||
balance-sheet.row.net-debt | -2692.08 | -646.2 | -595 | -825.4 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 284.9 | 228.3 | 421.3 | 361.5 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 6.41 | 113.9 | 99.8 | 89.5 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.3 | 14.4 | 25.6 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.3 | -14.4 | -25.6 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 15.41 | 113.7 | 129.1 | 197.9 | ||||||||||||||||||||
cash-flows.row.account-receivables | 19.66 | 82.9 | 108.6 | 198.8 | ||||||||||||||||||||
cash-flows.row.inventory | -4.25 | 0.6 | -11.5 | -3.7 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 36.6 | 17.5 | -22.7 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.3 | 14.4 | 25.6 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 269.47 | -66.1 | -185.6 | -233.1 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 481.62 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -213.1 | -163.5 | -236.9 | -255.9 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.01 | -3.4 | 16.5 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | -582.01 | -1247.4 | -1061 | -1517.2 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 487.59 | 896.1 | 1092.6 | 964.3 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -71.42 | -22.2 | -9 | -33.3 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -383.53 | -540.4 | -197.8 | -842.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -11 | -5.6 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -102.7 | -102.9 | -205.8 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 10.6 | 4.5 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -110.25 | -102.7 | -103.3 | -206.9 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.03 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -153.55 | -253.2 | 163.5 | -633.1 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 2465.46 | 527.2 | 780.4 | 617 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2619.01 | 780.4 | 617 | 1250.1 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 481.62 | 389.8 | 464.6 | 415.8 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -213.1 | -163.5 | -236.9 | -255.9 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 268.53 | 226.3 | 227.7 | 159.9 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 962.21 | 1008.3 | 1050.2 | 1214.8 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 238.91 | 305.5 | 157 | 183.6 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | 723.3 | 702.8 | 893.2 | 1031.2 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 166.1 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 19.27 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 214.73 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | -0.99 | -1 | 99.2 | 82.7 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 498.87 | 491.6 | 711.2 | 776.1 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 737.77 | 797.1 | 868.2 | 959.7 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 14.77 | 14.2 | 15.2 | 16.8 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0.2 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 214.73 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 53.63 | 241.5 | -4 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -0.99 | -1 | 99.2 | 82.7 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 53.63 | 241.5 | -4 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0.2 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 52.83 | 145.7 | 161 | 134.8 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 348.88 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | 239.31 | 211.1 | 263.3 | 457.5 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | 292.94 | 452.6 | 259.4 | 457.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 22.25 | 49.9 | 31 | 36.5 | |||||||||||||||||||||||
income-statement-row.row.net-income | 284.9 | 416.7 | 234.4 | 425.9 |
Często zadawane pytania
Ile wynosi Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) aktywów ogółem?
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) całkowite aktywa to 6277761845.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 482153895.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.752.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 0.261.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.296.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.249.
Co to jest Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 416691942.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 37593280.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 491631884.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 643139595.000.